Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology

Experimental Physiology

Volumn 93, Issue 1, 2008, Pages 148-154

  Wray, Jessica ^a   Bishop Bailey, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 8,9 EPOXYICOSATRIENOIC ACID; CYTOCHROME P450 2C; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; DRUG METABOLITE; EPOXYICOSATRIENOIC ACID; LIPID; OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROADIFEN; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

BLOOD VESSEL TONE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG EFFECT; FATTY ACID METABOLISM; HUMAN; MAMMAL; NONHUMAN;

EID: 37349125921     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.038612     Document Type: Conference Paper

References (76)

1. Abraham NG, Pinto A, Mullane KM, Levere RD & Spokas E (1985). Presence of cytochrome P450-dependent monooxygenase in intimal cells of the hog aorta. Hypertension 7, 899 904.
2. Ca channels. Circulation 107, 769 776.
3. Bernstrom K, Kayganich K, Murphy RC & Fitzpatrick FA (1992). Incorporation and distribution of epoxyeicosatrienoic acids into cellular phospholipids. J Biol Chem 267, 3686 3690.
4. Bishop-Bailey D & Wray J (2003). Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 71, 1 22.
5. 2+ changes and dilation in isolated resistance arteries. FASEB J 14, 255 260.
6. Brown HF (1982). Electrophysiology of the sinoatrial node. Physiol Rev 62, 505 530.
7. Campbell WB, Gebremedhin D, Pratt PF & Harder DR (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78, 415 423.
8. Capdevila JH, Mosset P, Yadagiri P, Lumin S & Falck JR (1988). NADPH-dependent microsomal metabolism of 14,15-epoxyeicosatrienoic acid to diepoxides and epoxyalcohols. Arch Biochem Biophys 261, 122 133.
9. Carroll MA & McGiff JC (2000). A new class of lipid mediators: cytochrome P450 arachidonate metabolites. Thorax 55, S13 S16.
10. Chen J, Capdevila JH, Zeldin DC & Rosenberg RL (1999). Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55, 288 295.
11. Chinetti G, Fruchart JC & Staels B (2001). Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 90, 125 132.
12. Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR & Capdevila JH (2002). The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277, 35105 35112.
13. Daikh BE, Lasker JM, Raucy JL & Koop DR (1994). Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 271, 1427 1433.
14. Desvergne B & Wahli W (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649 688.
15. Duval C, Chinetti G, Trottein F, Fruchart JC & Staels B (2002). The role of PPARs in atherosclerosis. Trends Mol Med 8, 422 430.
16. Fabiato A & Fabiato F (1979). Calcium and cardiac excitation-contraction coupling. Annu Rev Physiol 41, 473 484.
17. Fang X, Hu S, Xu B, Snyder GD, Harmon S, Yao J, Liu Y, Sangras B, Falck JR, Weintraub NL & Spector AA (2006). 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-α. Am J Physiol Heart Circ Physiol 290, H55 H63.
18. 2 production in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 275, H2113 H2121.
19. Fang X, VanRollins M, Kaduce TL & Spector A (1995). Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. J Lipid Res 36, 1236 1246.
20. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R & Fleming I (2000). Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 36, 270 275.
21. Fisslthaler B, Michaelis UR, Randriamboavonjy V, Busse R & Fleming I (2003). Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta 1619, 332 339.
22. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I & Busse R (1999). Cytochrome P450, 2C is an EDHF synthase in coronary arteries. Nature 401, 493 497.
23. + elevation in in situ pig hearts. Circulation 90, 3009 3017.
24. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP & Busse R (2001). Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88, 44 51.
25. Fredenrich A & Grimaldi PA (2005). PPARδ: an uncompletely known nuclear receptor. Diabetes Metab 31, 23 27.
26. Fulton D, Mahboubi K, McGiff JC & Quilley J (1995). Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 114, 99 102.
27. Gettes LS & Reuter H (1974). Slow recovery from inactivation of inward currents in mammalian myocardial fibres. J Physiol 240, 703 724.
28. 2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid. J Biol Chem 272, 29546 29553.
29. Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB & Roman R (1994). Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol Heart Circ Physiol 266, H2098 H2107.
30. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR & Roman RJ (1996). Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol Regul Integr Comp Physiol 270, R217 R227.
31. Ito O, Onso-Galicia M, Hopp KA & Roman RJ (1998). Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol Renal Physiol 274, F395 F404.
32. Johnson AR, Revtyak G & Campbell WB (1985). Arachidonic acid metabolites and endothelial injury: studies with cultures of human endothelial cells. Fed Proc 44, 19 24.
33. Jones DC, Ding X & Daynes RA (2002). Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277, 6838 6845.
34. Karara A, Dishman E, Falck JR & Capdevila JH (1992). Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266, 7561 7569.
35. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM & Kliewer SA (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270, 12953 12956.
36. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD & Shyy JY (2005). The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102, 16747 16752.
37. Marx N, Sukhova GK, Collins T, Libby P & Plutzky J (1999). PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, 3125 3131.
38. Michaelis UR, Falck JR, Schmidt R, Busse R & Fleming I (2005a). Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol 25, 321 326.
39. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I & Busse R (2005b). Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118, 5489 5498.
40. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I & Busse R (2003). Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17, 770 772.
41. Moffat MP, Ward CA, Bend JR, Mock T, Farhangkhoee P & Karmazyn M (1993). Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol Heart Circ Physiol 264, H1154 H1160.
42. Moraes LA, Piqueras L & Bishop-Bailey D (2006). Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110, 371 385.
43. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC & Liao JK (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276 1279.
44. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK & Milburn MV (1998). Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137 143.
45. Omata K, Abraham NG & Schwartzman ML (1992). Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am J Physiol Renal Physiol 262, F591 F599.
46. Ortiz De Montellano PR (1995). Oxygen activation and reactivity. In Cytochrome P450: Structure, Mechanism and Biochemistry, 2nd edn, ed. Ortiz De Montellano PR, pp. 245 304. Plenum Press, New York.
47. Passauer J, Pistrosch F, Lassig G, Herbrig K, Bussemaker E, Gross P & Fleming I (2005). Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney Int 67, 1907 1912.
48. Pinto A, Abraham NG & Mullane KM (1987). Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther 240, 856 863.
49. Ricote M, Li AC, Willson TM, Kelly CJ & Glass CK (1998). The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79 82.
50. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC & Delhon A (2002). PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435, 143 151.
51. Rosolowsky M, Falck JR & Campbell WB (1996). Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and ω-oxidized metabolites. Biochim Biophys Acta 1300, 143 150.
52. Rubanyi GM & Vanhoutte PM (1987). Nature of endothelium-derived relaxing factor: are there two relaxing mediators? Circ Res 61, II61 II67.
53. Ryoo S, Won M, Kim DU, Kim L, Han G, Park SK, Mukaida N, Maeng P, Yoo HS & Hoe KL (2004). PPARα activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem Biophys Res Commun 318, 329 334.
54. Scarborough PE, Ma J, Qu W & Zeldin DC (1999). P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31, 205 234.
55. + channels and p42/p44 MAPK pathway. Circ Res 95, 506 514.
56. Sher T, Yi HF, McBride OW & Gonzalez FJ (1993). cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32, 5598 5604.
57. Singer HA, Saye JA & Peach MJ (1984). Effects of cytochrome P-450 inhibitors on endothelium-dependent relaxation in rabbit aorta. Blood Vessels 21, 223 230.
58. Spearman ME, Prough RA, Estabrook RW, Falck JR, Manna S, Leibman KC, Murphy RC & Capdevila J (1985). Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Arch Biochem Biophys 242, 225 230.
59. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J & Tedgui A (1998). Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790 793.
60. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS & Liao JK (2002). Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90, 1020 1027.
61. Tontonoz P, Hu E, Graves RA, Budavari AI & Spiegelman BM (1994). mPPAR γ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8, 1224 1234.
62. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P & Spector AA (1999). Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol Heart Circ Physiol 277, H2098 H2108.
63. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ & Glass CK (2003). PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci U S A 100, 6712 6717.
64. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR & Zeldin DC (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272, 12551 12559.
65. Wu S, Moomaw CR, Tomer KB, Falck JR & Zeldin DC (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271, 3460 3468.
66. 2+ channels and contraction in mammalian heart cells. J Physiol 508, 777 792.
67. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA & Milburn MV (1999). Molecular recognition of fatty acids by peroxisome proliferator- activated receptors. Mol Cell 3, 397 403.
68. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr., McKee DD, Moore JT & Willson TM (2001a). Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98, 13919 13924.
69. Xu X, Otsuki M, Saito H, Sumitani S, Yamamoto H, Asanuma N, Kouhara H & Kasayama S (2001b). PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells. Endocrinology 142, 3332 3339.
70. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK & Zeldin DC (2001). Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60, 310 420.
71. Zeldin DC, DuBois RN, Falck JR & Capdevila JH (1995a). Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322, 76 86.
72. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR & Capdevila JH (1993). Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268, 6402 6407.
73. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD & Wu S (1996). Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330, 87 96.
74. Zeldin DC, Plitman JD, Kobayashi J, Miller RF, Snapper JR, Falck JR, Szarek JL, Philpot RM & Capdevila JH (1995b). The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest 95, 2150 2160.
75. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR & Capdevila JH (1995c). Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys 316, 443 451.
76. Zhang B, Berger J, Hu E, Szalzowski D, White-Carrington S, Spiegelman BM & Moller DE (1996). Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α. Mol Endocrinol 10, 1457 1466.